Progressive Reports March 2025 Results
Tweet
Share
E-mailGet Alerts PGR Hot Sheet
Price: $204.87 --0%
EPS Growth %: -19.6%
Financial Fact:
Net effect of dilutive stock-based compensation: 3.1M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -19.6%
Financial Fact:
Net effect of dilutive stock-based compensation: 3.1M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
The Progressive Corporation (NYSE: PGR) today reported the following results for the month and quarter ended March 31, 2025:
| March | Quarter | |||||||||||||||||||
| (millions, except per share amounts and ratios; unaudited) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||
| Net premiums written | $ | 9,041 | $ | 7,746 | 17 | % | $ | 22,206 | $ | 18,962 | 17 | % | ||||||||
| Net premiums earned | $ | 6,787 | $ | 5,634 | 20 | % | $ | 19,409 | $ | 16,149 | 20 | % | ||||||||
| Net income | $ | 522 | $ | 893 | (42 | ) | % | $ | 2,567 | $ | 2,331 | 10 | % | |||||||
| Per share available to common shareholders | $ | 0.89 | $ | 1.52 | (42 | ) | % | $ | 4.37 | $ | 3.94 | 11 | % | |||||||
| Total pretax net realized gains (losses) on securities | $ | (211 | ) | $ | 59 | (458 | ) | % | $ | (212 | ) | $ | 156 | (236 | ) | % | ||||
| Combined ratio | 90.9 | 84.3 | 6.6 | pts. | 86.0 | 86.1 | (0.1 | ) | pts. | |||||||||||
| Average diluted equivalent common shares | 587.7 | 587.4 | 0 | % | 587.7 | 587.3 | 0 | % | ||||||||||||
| March 31, | |||||
| (thousands; unaudited) | 2025 | 2024 | % Change | ||
| Policies in Force | |||||
| Personal Lines | |||||
| Agency – auto | 10,146 | 8,593 | 18 | ||
| Direct – auto | 14,771 | 11,855 | 25 | ||
| Special lines | 6,637 | 6,076 | 9 | ||
| Property | 3,576 | 3,209 | 11 | ||
| Total Personal Lines | 35,130 | 29,733 | 18 | ||
| Commercial Lines | 1,162 | 1,101 | 6 | ||
| Companywide | 36,292 | 30,834 | 18 | ||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- John Swann of SPX Technologies to retire in January 2027
- Regenxbio shares jump after FDA agrees to reverse drug rejection
- NIQ expands GeoPurchase audiences to four new countries
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
